GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis

Dahabreh, IJ; Giannouli, S; Gota, V; Voulgarelis, M

dc.contributor.author	Dahabreh, IJ	en
dc.contributor.author	Giannouli, S	en
dc.contributor.author	Gota, V	en
dc.contributor.author	Voulgarelis, M	en
dc.date.accessioned	2014-03-01T11:46:26Z
dc.date.available	2014-03-01T11:46:26Z
dc.date.issued	2010	en
dc.identifier.issn	0020-7136	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37906
dc.subject	glutathione-S-transferace	en
dc.subject	GSTT1	en
dc.subject	GSTM1	en
dc.subject	myelodysplastic syndrome	en
dc.subject	meta-analysis	en
dc.subject.classification	Oncology	en
dc.subject.other	GLUTATHIONE-S-TRANSFERASE	en
dc.subject.other	ACUTE MYELOID-LEUKEMIA	en
dc.subject.other	MYELOPROLIFERATIVE DISORDERS	en
dc.subject.other	GENETIC POLYMORPHISMS	en
dc.subject.other	CLINICAL-TRIALS	en
dc.subject.other	LUNG-CANCER	en
dc.subject.other	BENZENE	en
dc.subject.other	EXPOSURE	en
dc.subject.other	GENOTYPE	en
dc.subject.other	DEFECT	en
dc.title	GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis	en
heal.type	other	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Glutathione-S-transferace polymorphisms may make hematopoietic lineage cells susceptible to genotoxicity following exposure to heavy metals or benzene. We conducted a systematic review and meta-analysis to define the effect of GSTM1 and GSTT1 null polymorphisms on MDS risk. We searched the PubMed and SCOPUS databases to identify peer-reviewed published case-control studies investigating the association between GSTT1 and/or GSTM1 null genotypes and development of MDS. Between-study heterogeneity was assessed using Cochran's Q statistic and the I-2 statistic. Odds ratios from individual studies were pooled using fixed and random effects models. Thirteen studies were considered eligible for the GSTT1 meta-analysis (1471 cases, 1907 controls) and 10 were considered eligible for the GSTM1 meta-analysis (1161 cases, 1668 controls). For the GSTT1 polymorphism, there was moderate between study heterogeneity (p(Q) = 0.01; I-2 = 52.3%) and the null genotype was significantly associated with increased risk of MDS development, random effects OR = 1.43 (95% CI, 1.09-1.89); p = 0.01. For the GSTM1 polymorphisms there was moderate between-study heterogeneity (p = 0.07; I-2 = 43.1%) and the random effects OR = 1.02 (95% CI, 0.82-1.28) was non-significant (p = 0.85). The GSTT1 null genotype is a significant risk factor for MDS development. Gene-environment interactions need to be further explored.	en
heal.publisher	JOHN WILEY & SONS INC	en
heal.journalName	INTERNATIONAL JOURNAL OF CANCER	en
dc.identifier.isi	ISI:000274940200018	en
dc.identifier.volume	126	en
dc.identifier.issue	7	en
dc.identifier.spage	1716	en
dc.identifier.epage	1723	en